Karen Zagar, MD
Rheumatology · Palm Harbor, FLNPI 1902889587
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 1,194 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations.
Across 1,194 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- AbbVie$3K
- Novartis$2K
- GSK$2K
- Pfizer$2K
- E.r. Squibb & Sons, L.L.C.$1K
- plus $9K from 34 others
Across 350 payments — averaging $2038.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$447K
- UCB SA$76K
- Gilead$49K
- Pfizer$43K
- Novartis$33K
- Eli Lilly$21K
- plus $44K from 7 others
What the payments were for
- Speaking & faculty fees$4002%
- Food & beverage$22,10097%
- Education$2241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 228 | $3,861 |
| AbbVie | 121 | $3,142 |
| Novartis | 110 | $1,776 |
| GSK | 95 | $1,612 |
| Pfizer | 85 | $1,500 |
| E.r. Squibb & Sons, L.L.C. | 64 | $1,353 |
| UCB, Inc. | 84 | $1,287 |
| Mallinckrodt Hospital Products Inc. | 52 | $1,280 |
| Johnson & Johnson | 57 | $1,178 |
| Radius Health, Inc. | 42 | $733 |
| Boehringer Ingelheim | 41 | $731 |
| Lilly USA, LLC | 38 | $726 |
| AstraZeneca(2 entities) | 28 | $636 |
| Sanofi | 26 | $617 |
| Sobi, Inc | 22 | $390 |
| Fresenius Kabi USA, LLC | 18 | $378 |
| Genentech USA, Inc. | 19 | $277 |
| Aurinia Pharma U.S., Inc. | 8 | $172 |
| Antares Pharma, Inc. | 8 | $143 |
| Dexcom, Inc. | 7 | $125 |
| Mallinckrodt Enterprises LLC | 7 | $123 |
| Novo Nordisk | 4 | $94 |
| Sandoz | 4 | $74 |
| Corcept Therapeutics | 3 | $52 |
| ANI Pharmaceuticals, Inc. | 3 | $52 |
| Pacira Therapeutics, Inc. | 2 | $50 |
| IBSA Pharma Inc. | 2 | $47 |
| Bayer | 2 | $37 |
| Organon | 2 | $35 |
| Neurocrine Biosciences, Inc. | 1 | $30 |
| Ultragenyx Pharmaceutical Inc. | 1 | $26 |
| Mannkind Corporation | 1 | $26 |
| Verity Pharmaceuticals Inc. | 1 | $25 |
| Hikma Pharmaceuticals USA | 1 | $23 |
| Recordati_rare_diseases_inc. | 1 | $23 |
| Medexus Pharma, Inc. | 2 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Exact Sciences | 1 | $18 |
| Boston Scientific | 1 | $16 |
| Avion Pharmaceuticals | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,724 in reported general payments places this provider in the 80th percentile of 453 rheumatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 13 | $170,629 |
| EnbrelEtanercept | 22 | $163,463 |
| RinvoqUpadacitinib | 14 | $133,321 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 17 | $126,809 |
| ProliaDenosumab | 71 | $123,246 |
| OrenciaAbatacept/Maltose | 24 | $122,403 |
| Taltz AutoinjectorIxekizumab | 14 | $94,109 |
| TymlosAbaloparatide | 24 | $83,620 |
| Cimzia (2 Pack)Certolizumab Pegol | 14 | $82,471 |
| ActemraTocilizumab | 24 | $48,223 |
| Hydroxychloroquine Sulfate | 203 | $6,909 |
| MethotrexateMethotrexate Sodium | 326 | $6,243 |
| SavellaMilnacipran Hcl | 12 | $5,636 |
| Cevimeline Hcl | 15 | $4,979 |
| Leflunomide | 40 | $3,961 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel, Prolia | $3,861 | $286,71093 claims |
| AbbVieRinvoq, Savella | $3,142 | $138,95626 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $1,353 | $122,40324 claims |
| Radius Health, Inc.Tymlos | $733 | $83,62024 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,287 | $82,47114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 453 rheumatology providers in Florida.
Other rheumatology in Palm Harbor
- Anthony SebbaPalm Harbor$588K
- Alvin WellsDestin$2.4M
- Guillermo ValenzuelaPlantation$1.5M
- Julio Gonzalez-PaoliTampa$1.4M
- Ernesto RodriguezZephyrhills$958K
- Vinicius Costa Diniz DominguesDaytona Beach$921K
- Jonathan GreerBoynton Beach$757K
- Jigar ShahMargate$750K
- Rachel TateHollywood$729K
- Howard BuschLoxahatchee$717K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.